Logo image
Back
Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer
Journal article   Open access   Peer reviewed

Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer

Kiera Roubal, Zin W Myint and Jill M Kolesar
American journal of health-system pharmacy, Vol.77(5), pp.346-351
03/01/2020
DOI: 10.1093/ajhp/zxz329
PMID: 32073123
url
https://doi.org/10.1093/ajhp/zxz329View
Published (Version of record) Open Access

Abstract

To provide an overview of fibroblast growth factor receptor (FGFR) gene alterations and the pharmacology, clinical effectiveness, dosage and administration, cost, and place in therapy of erdafitinib in bladder cancer. Erdafitinib (Balversa, Janssen Pharmaceuticals) is a novel pan-FGFR inhibitor recently approved for the treatment of patients with advanced urothelial cancer with specific FGFR genetic alterations who have received at least one prior platinum-containing regimen. Erdafitinib binding to the FGFR2 and FGFR3 receptors inhibits FGF activity, resulting in cell death. Erdafitinib is available in tablet form, and the current recommended daily dosing is 8 mg, with dose escalation to 9 mg after 14 to 21 days of therapy if tolerated. A phase 2 clinical trial demonstrated that patients who received erdafitinib experienced on average 5.5 months of progression-free survival (95% confidence interval [CI], 4.2-6.0 months). In addition, 40% (95% CI, 31-50%) of patients responded to erdafitinib therapy. Patients receiving erdafitinib therapy should be monitored specifically for elevations in serum phosphate levels and changes in vision. Other adverse effects include anemia, thrombocytopenia, and electrolyte abnormalities. Erdafitinib is the first small-molecule FGFR inhibitor approved for use in advanced bladder cancer.
 Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Humans Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacology Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - pharmacology Quinoxalines - administration & dosage Quinoxalines - adverse effects Quinoxalines - pharmacology Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology

Details

Metrics

9 Record Views
50 Times Cited - Web of Science
Logo image